Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
2024年2月12日 - 9:13PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 12 February 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Ludovic Helfgott |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice President |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 824.00 |
20,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
20,000 sharesDKK 824.00 |
|
e) |
Date of the transaction |
2024-02-09 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Doug Langa |
|
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice President |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
4 |
Details of the transaction(s) |
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
b) |
Nature of the transaction |
Sale of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
DKK 823.83 |
19,461 shares |
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
19,461 sharesDKK 823.83 |
|
e) |
Date of the transaction |
2024-02-08 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656 azey@novonordisk.com |
|
Company Announcement No 13 / 2024
Novo Nordisk (TG:NOV)
過去 株価チャート
から 5 2024 まで 6 2024
Novo Nordisk (TG:NOV)
過去 株価チャート
から 6 2023 まで 6 2024